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Abstract 
 
The taste of pharmaceuticals strongly affects the compliance of patients. This study investigated the 
applicability of the electronic tongue and rodent brief-access taste aversion (BATA) model for the bitter 
compound praziquantel (PZQ) and taste masked liquid formulations for PZQ. In a comparative study 
maltodextrin (MD) Kleptose® linecaps 17 was selected as an alternative taste masking agent to two 
cyclodextrins; hydroxypropyl-beta-cyclodextrin (HP-β-CD) and sulfobutyl ether-beta-cyclodextrin (SBE-
β-CD). A phase solubility study showed the highest affinity and solubilization capabilities for SBE-β-CD 
over HP-β-CD and MD, suggesting the highest taste masking ability for SBE-β-CD. No reliable results 
were achieved for PZQ with the Insent electronic tongue. Thus this system was not used for further 
evaluation of solutions with MD and CDs to confirm the results of the solubility study. In contrast the 
BATA model demonstrated conclusive responses for the aversiveness of PZQ. The concentration of 
PZQ inhibiting 50% of water lick numbers (called IC50 value) was 0.06 mg/ml. In contrast to the phase 
solubility study, the MD enabled an equal taste masking effect in vivo in comparison to both CDs. 
Moreover HP-β-CD showed superior taste masking capabilities for PZQ compared to SBE-β-CD as the 
SBE-β-CD itself was less acceptable for the rodents than HP-β-CD. In conclusion, the BATA model was 
identified as a more efficient taste assessment tool for the pure PZQ and liquid formulations in contrast 
to the electronic tongue and the phase solubility study.  
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1. Introduction 
Taste masking of drugs is of particular importance for the adherence of patients, especially for children 
or in the veterinary area for picky animals like cats (Walsh et al., 2014). It is reasonable to screen 
molecules and clinical formulations regarding their taste as early as possible to save costs in the product 
development of a compound. Due to ethical and toxicological reasons human studies are not possible 
to perform at an early stage, especially for challenging patient groups like children (Pein et al., 2014). 
Alternative reported non-human taste assessment tools include in vivo methods such as animal 
preference tests using dogs, cats, rats or mice or even fish or drosophila and electrophysiological 
methods in primates. Furthermore, in vitro methods were developed despite drug release studies which 
are mostly based on determined taste thresholds in humans. Such in vitro methods involve electronic 
taste-sensing systems (electronic tongues) or cell based systems using calcium imaging (Mohamed-
Ahmed et al., 2016; Slack et al., 2010). The most useful non-human taste assessment tools are the 
electronic tongue and the BATA model (Mohamed-Ahmed et al., 2016). 
Electronic tongues are artificial taste assessment tools (Pein et al., 2015). They are analytical sensor 
array systems characterizing pure substances or formulations in aqueous solutions. The equipped 
sensors vary in their composition and properties resulting in a selectivity for different substances. The 
applied measurement principle can be based on potentiometry, voltammetry, amperometry or others 
(Khan and Kang, 2015). In accordance to the human taste the activity of a compound logarithmically 
affects the measured signals of the electronic tongue (Woertz et al., 2010, 2011c). Various studies 
focused on the implementation of these systems for taste assessment in pharmaceutical formulation 
development for liquid and solid dosage forms and demonstrated correlations to human taste panels 
(Eckert et al., 2013; Haraguchi et al., 2016; Pimparade et al., 2015; Preis et al., 2012; Rudnitskaya et 
al., 2013; Wesoły et al., 2017; Woertz et al., 2011a; Woertz et al., 2011b; Woertz et al., 2011c). 
Electronic tongues are preferable over human taste panels in terms of safety, toxicity and objectivity. 
They can provide an early screening of new drugs of unknown toxicity and the relative optimization of 
preclinical formulations (Mohamed-Ahmed et al., 2016). As a prerequisite for the assessment of 
multicomponent solutions, a calibration for the pure compounds needs to be performed proving a 
concentration dependent signal. Subsequently mixtures can be compared regarding their taste masking 
using multivariate data analysis (Lorenz et al., 2009).  
Besides the electronic tongue and in terms of readiness, the rodent brief-access taste aversion (BATA) 
model is the most useful non-human taste assessment tool. Indeed various parameters (necessary time 
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for data collection, ability to screen pure drugs and formulations, correlation to human in vivo data, 
validation potential and costs) were graded higher comparatively to other tools by Mohamed-Ahmed et 
al (Mohamed-Ahmed et al., 2016). Several studies showed the great potential of rat models designed 
for the measurement of the palatability of different compounds (Bhat et al., 2005) and the correlation to 
human taste panels (Clapham et al., 2012; Devantier et al., 2008; Noorjahan et al., 2014; Rudnitskaya 
et al., 2013; Soto et al., 2016). In the BATA model, samples are presented randomly to rats or mice in 
several sipper tubes and the number of licks recorded electronically by a lickometer is inversely 
proportional to the aversiveness of the samples (Soto, 2016). Due to the short period of time of exposure 
to samples, the intake of each compound is limited, to avoid toxic side effects. New chemical entities 
with unknown toxicity and well-known pharmaceutical compounds can be screened in early 
development as pure drugs or in preclinical or clinical formulations (Mohamed-Ahmed et al., 2016).  
An example for a compound with an unpleasant taste is praziquantel (PZQ). It is an anthelminthic drug 
that is used in adults and children against schistosomiasis and worm infections in animals. It is currently 
used in mass control programs for morbidity control in school-age children and adults at risk (Meyer et 
al., 2009). A drawback is its intensive bitter and metallic taste, which is accompanied with poor 
compliance (Passerini et al., 2006).  
One approach to improve the taste of aversive compounds is the complexation with cyclodextrins (CDs). 
They are cyclic oligosaccharides (α-D-glucopyranose) obtained from starch shaped as truncated cones 
(Szente et al., 2016). Several interactions such as hydrogen bonds, van der Waals’, electrostatic, 
charge-transfer and hydrophobic binding lead to host-guest type inclusion complexes and partly or 
complete encapsulation of a drug (Loftsson and Brewster, 1996) providing increased drug solubility, 
bioavailability or stability and decreasing unpleasant taste and smell (Szejtli and Szente, 2005).The β-
CD and its derivatives, including hydroxypropyl-β-CD (HP-β-CD) and sulfobutyl ether-β-CD (SBE-β-CD)  
are the most commonly used CDs in pharmaceutical industry (Jambhekar and Breen, 2016) and were 
chosen for PZQ on the basis of previous studies (Becket et al., 1999). They are considered as safe as 
the daily oral dose for HP-β-CD in pharmaceuticals may reach 8 g/day (EMA, European Medicines 
Agency, 2014). Higher amounts showed an increase in the incidence in soft stools and diarrhea. Further 
findings upon oral administration where cecal enlargement and renal effects due to systemic absorption 
(Stella and He, 2008). There is no data available for children below two years (EMA, European 
Medicines Agency, 2014).  
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In addition maltodextrins (MDs) were investigated as they can also provide taste masking and solubility 
enhancement (Preis et al., 2014; Preis et al., 2012). With no limited daily intake (EFSA, European Food 
Safety Agency, 2013) and their wide use in infant formula and nutritional supply they represent a 
promising alternative to CDs. They consist of d-glucose units (amylose and amylopectin) connected in 
chains of variable length with α-1,4-glycosidic and few α-1,6-glycosidic bonds derived from starch. The 
incorporated amylose builds up a helical structure in aqueous media (Carbinatto et al., 2016). In this 
way maltodextrins can provide inclusion complexes by hydrophobic and van der Waals’ interactions and 
can encapsulate hydrophobic drugs (Kong and Ziegler, 2014; Luo et al., 2016; Ribeiro et al., 2017). 
Kleptose® linecaps 17 was chosen as the most promising MD due to its high amylose content and 
previous promising results regarding taste masking (Preis et al., 2014; Preis et al., 2012).  
Former studies reported the complexation mechanisms of PZQ with HP-β-CD and SBE-β-CD improving 
the solubility and the dissolution of the drug. None of them investigated their taste masking efficiency 
for PZQ in vivo in comparison to MD as a promising alternative to CDs. 
Therefore the aim of this study was to investigate alternative taste assessment tools to human taste 
panels for the bitter compound PZQ. The electronic tongue and the BATA model were chosen as the 
most promising taste screening tools. Firstly the applicability of both methods was evaluated for the pure 
compound PZQ. Secondly the efficacy of the BATA model was evaluated by comparing PZQ taste 
masking capabilities of aforementioned MD and CDs.   
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2. Materials and methods 
2.1. Materials 
Racemic Praziquantel was supplied by Merck KGaA (Darmstadt, Germany). Hydroxypropyl-beta-
cyclodextrin (HP-β-CD, Kleptose® HPB, 1387.2 g/mol) and maltodextrin (MD, Kleptose® linecaps 17, 
12635.0 g/mol) were purchased from Roquette (Lestrem, France). Sulfobutyl ether-beta-cyclodextrin 
(SBE-β-CD, Captisol®, 2163.0 g/mol) was received from CyDex Pharmaceuticals (Inc., Lawrence, 
Kansas).  
The following substances were used for the reference and washing solutions for the electronic tongue: 
potassium chloride (Gruessing GmbH, Filsum, Germany), tartaric acid (AppliChem GmbH, Darmstadt, 
Germany), quinine hydrochloride dihydrate (Buchler GmbH, Braunschweig, Germany), hydrochloric acid 
(Merck KGaA, Darmstadt, Germany), potassium hydroxide (Gruessing GmbH, Filsum, Germany), 
absolute ethanol (VWR international, Darmstadt, Germany) and distilled water obtained by in-lab 
distillation of demineralized water. Deionized water in the BATA-model was prepared by ion exchange. 
All samples of the phase solubility study were prepared with purified water produced by a Millipore-Milli-
Q® integral water purification system (Merck KGaA, Darmstadt, Germany). Acetonitrile and ethanol as 
LC-MS grade (LiChrosolv®) were provided by Merck KGaA (Darmstadt, Germany).  
Self-developed electronic tongue sensors were prepared using Polyvinyl chloride (PVC, Sigma-Aldrich, 
Steinheim, Gemany) as polymer, isopropylmyristate (IPM, Cognis GmbH, Duesseldorf, Germany) as 
plasticizer, either tetra-dodecyl ammonium bromide (TB, Sigma-Aldrich), trioctylmethyl ammonium 
chloride (TC, Alfa Aesar, Karlsruhe, Germany) or bis(2-ethylhexyl) phosphate (BP, Sigma-Aldrich, 
Steinheim, Germany) as artificial lipids, oleic acid (OA, Fluka Analytical, Steinheim, Germany) and either 
hydroxypropyl-ß-cyclodextrin (HPßCD, Roquette, Lestrem, France) or a cyclodextrin oligomer (CDO, 
HHU, Duesseldorf, Germany) as ionophores and tetrahydrofuran (THF, VWR international, Darmstadt, 
Germany), absolute ethanol (Sigma-Aldrich, Steinheim, Germany) and acetone (VWR international, 
Darmstadt, Germany) as solvents for the membrane preparation.  
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2.2. Methods 
 
2.2.1. Phase solubility study with maltodextrin and cyclodextrins 
A phase solubility study according to the experimental design of Higuchi and Connors (Higuchi and 
Connors, 1965) and Loftsson (Loftsson et al., 2007) was conducted to compare the solubility and 
resulting taste masking capabilities of the maltodextrin (MD) Kleptose® linecaps 17 and the cyclodextrins 
(CDs) Kleptose® HPB (HP-β-CD) and Captisol® (SBE-β-CD) in vitro.  
Excess amounts of PZQ (10-fold) were added to aqueous solutions of 2, 5, 10, 15 and 20 mM of the 
MD or the CDs (n = 3). After stirring for seven days at ambient temperature to reach an equilibrium, the 
suspensions were filtered through 0.45 µm PTFE membrane filters (VWR Chemicals, Leuven, Belgium). 
The solubilized drug content was determined via high performance liquid chromatography. The results 
were plotted against the used concentration of the MD or CDs. The apparent stability constant (K1:1) and 
the complexation efficiency (CE) were calculated as follows: 
 
K1:1 =   slope/(S0 (1 − slope) )            (1) 
 
CE =   slope/(1 − slope) =  [PZQ/CD]/[CD]          (2) 
 
2.2.2. Analysis of drug content 
The solubilized drug content was determined via high performance liquid chromatography (HPLC) using 
an Agilent 1100 (Agilent Technologies, Santa Clara, USA) at 210 nm. The analysis was performed with 
a Waters Symmetry® column (Waters Symmetry® Shield RP 18, 150 x 4.6 mm 3.5 µm). Eluents were 
water and acetonitrile in a validated gradient method with a flow rate of 1.5 ml/min. 
 
2.2.3. In vitro taste assessment by electronic tongue 
The commercially available electronic tongue TS-5000Z (Insent Inc., Atsugi-chi, Japan) was used for 
the in vitro evaluation of the taste intensity of various PZQ concentrations. The system is composed of 
a sensor unit with a sample table with two circles of sample positions, two sensor heads with up to eight 
sensors at a robot arm and a data recording system.  
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2.2.3.1. Sensors 
The commercially available sensors (Insent Inc., Atsugi-chi, Japan) included in this study were SB2AC0, 
SB2AN0 and SB2BT0 (cationic and neutral bitter compounds), SB2AAE (umami), SB2CT0 (saltiness) 
and SB2CA0 (sourness). As the detection of non-ionic and slowly water soluble substances like PZQ is 
limited self-developed sensors were evaluated named as sensor A to G (Table 1). The self-developed 
sensors were prepared according to Immohr et al. (Immohr et al., 2016). All sensors were preconditioned 
in a standard solution (30 mM potassium chloride and 0.3 mM tartaric acid in distilled water) for one day. 
Prior to each measurement a sensor check was performed. 
 
2.2.3.2.  Preparation of reference and sample solutions 
A stock solution of 0.5 mM (0.16 mg/ml) PZQ in distilled water was prepared and further diluted to 0.1 
(0.032  mg/ml), 0.05 (0.016 mg/ml) and 0.01 mM (0.0032 mg/ml). Using 4 different concentrations a 
calibration curve was generated to assess reliable drug detection of all sensors. As an external standard 
quinine hydrochloride with a concentration of 0.5 mM in distilled water was used to monitor the results 
of each sensor over time and reduce fluctuations in the sensor signals. This is recommended as the 
sensor response is affected by the environment, e.g. the temperature, and the age of the sensor (Woertz 
et al., 2011a). 
 
2.2.3.3. Measurement setup 
The measurement circle started with three washing steps in a washing solution. For positively charged 
sensors this was conducted in the standard solution, for negatively charged sensors 100 mM 
hydrochloric acid and ethanol 30% (w/w) were used. Afterwards a sample was analyzed regarding its 
taste for 30 s followed by two short washing steps of 3 s and the detection of the aftertaste for 30 s. The 
aftertaste depicts the change of the membrane potential due to absorption (CPA) of the compound to 
the lipid membrane of the sensor. This was followed by washing steps ending in the next circle. Each 
sample was measured 5 times in a randomized order, but always starting with the reference solution to 
monitor the sensor response. 
 
2.2.3.4. Data analysis 
Univariate data analysis was applied for comparison of all sensors and concentrations of PZQ. The 
results are displayed as a change of the membrane potential in mV. They were calculated in relation to 
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the reference solution. The first two runs of each sample were discarded as they were considered as 
preconditioning of the sensors. Based on the last three results of each concentration the mean and 
standard deviations were calculated for the taste and aftertaste. 
 
2.2.4. In vivo taste assessment by Brief-Access Taste Aversion (BATA) model 
 
2.2.4.1. Animals 
The taste assessment was carried out with two groups of ten adult male Sprague-Dawley (Charles-
River, Kent, UK) in accordance with the UK Animals (Scientific Procedures) Act 1986 (Project License 
PPL 70/7668). They were housed in pairs in standard cages at 21 ± 2°C and 50 ± 10% humidity with a 
12:12 h light/dark cycle. All training and testing occurred during the light phase of the cycle. Animals 
had free access to chow (Harlan, Oxon, UK) and tap water except for training and testing periods where 
a water-restriction schedule occurred. Throughout the experiment, daily food and water consumption 
were monitored. As a safety and welfare measure it was checked that their weight did not drop below 
85% of their free feeding weight. 
 
2.2.4.2. Sample preparation 
To evaluate the feasibility and the reliable response of the rodents, 6 different concentrations of PZQ in 
in-lab deionized water were tested. A stock solution of 0.2 mg/ml of PZQ was prepared and diluted with 
deionized water to 0.005, 0.01, 0.03, 0.05 and 0.10 mg/ml. 
After this calibration the taste masking capabilities of the MD in comparison to both CDs was evaluated 
in vivo. Aqueous solutions of each excipient at 20 mM were prepared and excess amounts of PZQ were 
added as described in 2.2.1 to reach the maximum solubility of PZQ. The resulting suspensions were 
filtered through 0.45 µm PTFE membrane filters (VWR Chemicals, Leuven, Belgium). The final drug 
content was analyzed via HPLC. For comparison with the pure PZQ in deionized water, the PZQ 
concentrations in the mixtures were set to the IC50 value of 0.06 mg/ml, the maximum solubility of the 
pure PZQ of 0.2 mg/ml and the maximum reachable PZQ concentration of 0.27 mg/ml for the MD and 
1.3 mg/ml for both CDs. The concentrations were diluted with pure excipient solutions (20 mM) to reach 
the target concentrations.  
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2.2.4.3. Experiment procedure 
The experimental design consisted of two training and testing days. Each rat was water-deprived for 
22 h before each session (training and testing) and was then placed in a lickometer (Davis MS-160, 
DiLog Instruments, Tallahassee, Florida, USA) for a maximum session-length of 40 min. The initial days 
of the protocol were dedicated to training with sipper tubes presenting deionized water. During both 
testing days each sample was presented in a sipper tube randomly up to 4 times to each rat per day. 
The trial began when the rat took its first lick from the sipper tube, and ended eight seconds later when 
the shutter closed. The rats received a water rinse between samples for 2 s from a sipper tube to 
minimize carry over effects. After each testing periods they received tap water for one hour for 
rehydration. In sum, each sample was tested up to 8 times (4 times per testing day) to 10 rats resulting 
in a final number of 80 measurements per solution. The taste of each sample was assessed by the 
number of licks per 8 s recorded by the lickometer. As a reference deionized water or pure excipient 
solutions were assessed. The experimental procedure was described in detail and optimized in earlier 
studies (Soto, 2016). 
 
2.2.4.4. Data analysis 
All data sets of each concentration of PZQ or the formulations with MD or CDs were statistically 
analyzed. The IC50 value describing the concentration of PZQ inhibiting 50% of the maximum lick 
numbers compared to the reference (water) was calculated with an Emax model as described in earlier 
studies (Soto et al., 2015). In addition, the percentage of lick inhibition relatively to the reference was 
determined with the following equation: 
 
% inhibition of licks =  
N0licksreference− N0licksconcentration PZQ
N0licksreference
 x 100        (3) 
 
The results were classified as presented in Table 2.  
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2.2.5. Statistical analysis 
The data of the phase solubility study and the electronic tongue were expressed as the arithmetic mean 
± standard deviation (S.D.). All BATA results are expressed as the arithmetic mean ± standard error of 
the mean (S.E.M.). The software SigmaPlot (version 12.5, Systat Software, Erkrath, Germany) was used 
for all statistical analyses. Statistical comparisons of two groups were performed with the Mann-Whitney 
test (p ≤ 0.05). The Kruskal-Wallis test (p ≤ 0.05) was applied for more than two groups.   
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3. Results and discussion 
 
3.1. Comparative phase solubility study with maltodextrin and cyclodextrins 
The ability of MD to improve the solubility of PZQ and hence a taste masking ability was evaluated by 
conducting a phase solubility study (Higuchi and Connors, 1965) in comparison to CDs. 
Both CDs (HP-β-CD and SBE-β-CD) significantly increased the intrinsic solubility of PZQ in water 
(0.71 mM) up to 5 to 7-fold at the highest concentration of 20 mM CD (p < 0.001) (Fig. 1). These findings 
confirmed previous results of Arrua et al. (Arrua et al., 2015) and Maragos et al. (Maragos et al., 2009). 
A linear profile of the solubility increase of CDs indicated a stoichiometry of 1:1, a positive or negative 
deviation from linearity would be associated with a higher order interaction or a self-association of CDs 
(Loftsson et al., 2005). Whereas this conclusion is in line with Maragos et al. (Maragos et al., 2009), de 
Jesus et al. (de Jesus et al., 2006) and El-Arini et al. (El-Arini and Leuenberger, 1996), other studies 
reported a stoichiometry of 1:2 (Arrua et al., 2015).  
The apparent solubility constant K1:1 and the complexation efficiency (CE) were calculated from the 
slope of the plot (Table 3). SBE-β-CD showed the highest solubility enhancement and a CE of 0.26 
meaning that one out of five SBE-β-CD molecules complexed the drug. For HP-β-CD a lower CE of 0.16 
was observed. Less than one out of seven HP-β-CD molecules interacted with the drug. Loftsson et al. 
summarized the reported complexation studies appointing an average CE for HP-β-CD of 0.39 ± 0.47 
for 13 different drugs in water (Loftsson et al., 2007). High values for K1:1 above 1 x 105 M-1 can lead to 
negative effects on the bioavailability of a compound (Stella and He, 2008). A strong affinity of a CD to 
a specific compound can result in issues regarding the complete dissociation of the drug from the CD in 
the gut. As the K1:1 values for HP-β-CD and SBE-β-CD in this study are below this critical values no 
issues were anticipated in vivo.  
The calculations were not applicable for the MD as there was no remarkable slope of the phase solubility 
profile. A solubility enhancement as it was shown for loperamide, dextromethorphan or dimenhydrinate 
leading to a taste masking effect could not be demonstrated for PZQ (Preis et al., 2014; Preis et al., 
2012). The incorporated amylose builds up a helical structure in aqueous media (Carbinatto et al., 2016). 
In this way maltodextrins can provide hydrophobic and van der Waals’ interactions to hydrophobic drugs 
(Kong and Ziegler, 2014; Luo et al., 2016; Ribeiro et al., 2017). Nevertheless these findings could not 
be confirmed for PZQ in this phase solubility study (Fig. 1).  
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Based on this phase solubility study a higher taste masking ability of both CDs in comparison to the MD 
was expected. 
 
3.2. Electronic tongue 
Pure PZQ was tested with four different concentrations ranging from 0.01 mM to 0.5 mM in distilled 
water to generate a calibration curve by means of the electronic tongue. The concentration range was 
comparable to other studies with other compounds (Pein et al., 2015). The detection was evaluated with 
commercially available sensors (SB2AC0, SB2AN0, SB2AAE, SB2CT0, SB2CA0 and SB2BT0) and 
self-developed sensors named as sensor A to G (composition described in Table 1). The sensor 
responses were determined as the change of the membrane potential (Fig. 2). Depending on the 
composition of the sensor membrane negative or positive responses were obtained (Kobayashi et al., 
2010). None of the sensors supplied a concentration-dependent signal for PZQ in the full concentration 
range. The commercially available sensors SB2AC0, SB2AN0 and SB2CA0 indicated a log-linear 
response from 0.01 to 0.1 mM, but not for 0.5 mM limiting the usability. This can be explained by the 
non-ionic character and the low solubility of PZQ in water resulting in only minor effects on the 
membrane potential of all tested sensors. The change of membrane potential as the response of the 
sensor to a sample solution can be generated by different mechanisms. The initial membrane potential 
of each sensor is formed when the lipid membrane is immersed in the reference solution. An electrical 
double layer is created at the surface depending on the composition of the incorporated lipids in the 
membrane. On the one hand, compounds in the sample solution can affect the membrane potential by 
ions directly altering the double layer. On the other hand, molecules can prevent lipid molecule 
dissociation which is responsible for the initial membrane potential. Furthermore, bitter compounds 
adsorb to the hydrophobic parts of the lipid membrane modifying the potential due to a varied charge 
density (Immohr et al., 2016; Kobayashi et al., 2010). Thus, a limited detection of the sensors has been 
expected for the non-ionic PZQ providing too little conductivity. Furthermore it could be assumed that 
the adsorption of PZQ on the lipid membranes of all sensors is too low for reliable interaction and 
resulting measurement signals. Difficulties regarding the detection of other neutral compounds have 
been reported before for ibuprofen, caffeine (Woertz et al., 2011a) and acetaminophen (Woertz et al., 
2010). A higher concentration of PZQ could have improved the results but could not be provided due to 
the limited and pH independent solubility of PZQ in water. Modifying the media of the sample solution 
was not considered as previous studies demonstrated a shift to higher detection limits when evaluating 
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different pH values and ionic concentrations (Tissen, 2011). As a consequence the detection of PZQ 
needs to be improved by developing sensors providing a higher sensitivity for the compound (Immohr 
and Pein-Hackelbusch, re-submitted on 06.03.2017). 
The change of membrane potential caused by adsorption or so called aftertaste sensor responses (Fig. 
3) were smaller for the majority of the sensors due to the washing step in between. Sensor signals 
before and after washing were significantly (p < 0.05) different except for the sourness sensor SB2CA0 
(p > 0.05). The highest difference between measurements before and after washing were observed for 
the cationic bitterness sensor SB2AC0. At 0.5 mM CPA values were more than 8 times lower compared 
to the change of membrane potential before washing (p < 0.001). This could indicate an interaction of 
PZQ with SB2AC0. Nevertheless none of the sensors provided a concentration-dependent response. 
As similar to the previous experiment (Fig. 2) deviations between concentrations for each sensor are 
below the measured standard deviations and do not provide additional insights regarding the taste 
intensity of PZQ or the reasonable applicability of one of the sensors in this study. 
 
 
3.3. BATA model 
 
3.3.1. Evaluation of praziquantel 
As an alternative taste assessment tool, the BATA model was used for PZQ and liquid formulations with 
MD and CDs. A mean value of 44.7 licks ± 1.1 was observed for deionized water as the reference of all 
10 rats during both testing days of the pure compound. The water-deprivation of 22 h was suitable to 
encourage the rats to drink from the various sipper tubes.  
The number of licks decreased with increasing concentration of PZQ (Fig. 4 and Fig. S1). PZQ was 
fully tolerated and did not show a significant decrease in number of licks at the concentration of 
0.005 mg/ml (45.3 ± 0.9 licks, 0 ± 1.2% lick inhibition) and 0.01 mg/ml (43.6 ± 1.2 licks, 1.2 ± 2.4% lick 
inhibition) in comparison to deionized water (p = 0.896 and 0.206). For a higher concentration of 
0.03 mg/ml a significant decrease in lick number (32.9 ± 1.7 licks) was observed (p < 0.001), but was 
still well tolerated (26.4 ± 3.9% lick inhibition). An increase to 0.05 mg/ml PZQ was tolerated (34.6 ± 
4.1%) with 29.2 ± 1.8 licks. The taste of PZQ was perceived aversive at 0.1 and 0.2 mg/ml (19.1 ± 
1.5 licks, 57.3 ± 0.2% lick inhibition and 12.5 ± 1.2 licks, 72.0 ± 2.6% lick inhibition). 
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The IC50 value was determined as 0.06 mg/ml (95% CI 0.049-0.082). Thus PZQ showed an extreme 
aversive taste in the range of quinine hydrochloride (Soto et al., 2015), worse than other bitter 
compounds such as sildenafil citrate, caffeine citrate, diclofenac or paracetamol (Soto, 2016; Soto et al., 
2016). These findings underline the importance of the taste masking for PZQ for the in use palatability 
of drug products. The individual lick profiles for each rat demonstrate the sensitivity of all rats for PZQ. 
All rats responded with a decreasing number of licks with an increasing PZQ concentration. This is of 
high importance as it is well-known that mammalians vary greatly in their taste perception of bitter 
compounds due to a variability in receptor gene expression in the mouth (Behrens and Meyerhof, 2009; 
Reed et al., 2006). The variability of both testing sessions (day 1 and day 2) was not significant (p > 
0.1). Thus the rats did not get used to the aversiveness of PZQ. Furthermore this low variability 
strengthens the reliability of the results.  
 
3.3.2. Comparative evaluation of maltodextrin and cyclodextrins 
Three different concentrations of PZQ were tested with 20 mM MD or CDs. For comparison with pure 
PZQ in deionized water, the PZQ concentrations in the mixtures were set to the IC50 value of 0.06 mg/ml, 
the maximum solubility of the pure PZQ of 0.2 mg/ml and the maximum reachable PZQ concentration 
of 0.27 mg/ml in solution with MD and 1.3 mg/ml in solution with CDs. 
The taste of pure 20 mM HP-β-CD (55.5 ± 1.2 licks) was similar to water (56.7 ± 1.4 licks) (p = 0.149) 
(Fig. 5 and Fig. S2). However, pure 20 mM SBE-β-CD did significantly decrease the lick number to 43.2 
± 2.4 (p < 0.001). Yet, the profiles for formulations at 0.06 and 0.2 mg/ml indicate a taste masking effect 
for both CDs. The lick numbers measured at 0.06 mg/ml for PZQ with HP-β-CD (53.5 ± 1.8 licks) and 
SBE-β-CD (44.0 ± 2.2 licks) did not significantly differ from the pure excipient solutions (p = 0.119 and 
0.616) indicating that these formulations were well tolerated by the rats (Table 4). In contrast, the pure 
PZQ was aversive/ untolerated at 0.06 mg/ml (IC50 value). The measured lick numbers significantly 
decreased for both CD formulations of 0.2 and 1.3 mg/ml (p < 0.001), but were better accepted at 
0.2 mg/ml than the pure PZQ solution. The complexation of PZQ with CDs improved the solubility of 
PZQ to 1.3 mg/ml but did not achieve a taste masking. As the complexation of PZQ and CDs is an 
equilibrium, free drug molecules are in solution (Loftsson et al., 2005). The amount of this free 
uncomplexed molecules increased with increasing drug concentration which might have lead in turn to 
a higher taste perception in the rats.  
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HP-β-CD showed a significant higher numbers of licks (p < 0.001) than SBE-β-CD at all concentrations. 
These findings are contrary to the results of the phase solubility study. SBE-β-CD led to a higher linear 
increase of the solubility of PZQ resulting in a higher K1:1 and CE than HP-β-CD (Fig. 1). Thus it was 
thought that this higher affinity of PZQ to SBE-β-CD would lead to a higher taste masking efficiency. 
However, the interaction and complexation of PZQ with the CDs is a rapid equilibrium with free drug and 
CD molecules. Arrua et al. (Arrua et al., 2015) described the presence of free PZQ in complexes with 
CDs. Moreover, CDs can form inclusion and non-inclusion complexes where the compounds interaction 
is located on the surface of the CD (Loftsson et al., 2007). In this way the compound is not shielded 
completely for taste perception and the affinity of the drug to the CD might not be solely representative 
for the taste-masking effect. In addition, the results of the pure excipients outlined an aversiveness of 
the pure SBE-β-CD in comparison to the pure HP-β-CD. In this study, the phase solubility results were 
not predictive for the in vivo taste assessment in the BATA model.  
The MD did not affect the number of licks in comparison to water (p = 0.810) (Fig. 5 and Fig. S2). The 
solution was fully tolerated according to the % lick inhibition (Table 4). In contrast to our expectations 
based on the phase solubility study, the BATA model revealed a taste masking effect of the MD up to 
0.06 mg/ml PZQ. The result for this PZQ concentration did not differ significantly from the pure excipient 
(p = 0.092) and was well tolerated. Increasing the concentration of PZQ up to 0.2 and 0.27 mg/ml 
decreased the number of licks significantly to 39.5 ± 2.9 and 32.2 ± 2.4 licks (p < 0.001), but the solutions 
were still classifiable as tolerated. This can be explained by the helical structure of the incorporated 
amylose providing a barrier between PZQ and the taste buds in the mouth of the rats resulting in a 
decreased taste perception (Carbinatto et al., 2016). As previously mentioned MDs can provide inclusion 
complexes by hydrophobic and van der Waals’ interactions and can encapsulate hydrophobic drugs just 
as CDs (Kong and Ziegler, 2014; Luo et al., 2016; Ribeiro et al., 2017). In the case of PZQ this did not 
affect the solubility of PZQ but could have resulted in the lower aversiveness of the solutions. Moreover 
the high amount of MD in the solution could also have led to an increased viscosity and consequently 
to a taste masking effect drug by decreasing the diffusion of PZQ to the taste buds (Walsh et al., 2014). 
It should be considered that the molecular weight of the MD is much higher in comparison to the CDs. 
Solutions with CDs contained 2 – 4% (w/w) in comparison to 25% (w/w) with MDs. Nevertheless, as 
there is no limited daily intake for MDs the concentration could even be increased to 30 to 40% (w/w) 
as it is common in syrups.  
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The taste masking of 0.06 mg/ml PZQ was achieved by using 20 mM of either MD or HP-β-CD. SBE-β-
CD was significantly less effective (p < 0.001). At higher concentrations (0.2 mg/ml), there was 
significant reduction of licks for all the formulations regardless of the taste masking agent used.  
However, the formulation with SBE-β-CD was still significantly less useful compared to the other 
formulations containing MD or HP-β-CD (p < 0.001). Formulations with MD and HP-β-CD were tolerated 
by the rats with no significant difference between the number of licks (p = 0.865). 
With regard to the final dosage form MDs would be preferable over CDs due to various reasons such 
as excipient costs and safety. A liquid formulation development with CDs would not be favorable due to 
the necessary high volume (> 27 ml/kg bodyweight) of one dose of PZQ. Assuming a single dose of 40 
mg/kg bodyweight of PZQ, already a child of 10.3 kg (2 years) would exceed the acceptable daily oral 
dose for HP-β-CD of 8 g/day. Maltodextrins with no limited daily intake offer a promising alternative in 
drug product development especially for liquid dosage forms, e.g. in terms of a syrup.  
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4. Conclusion 
The electronic tongue and the BATA model were used as alternative taste assessment tools to human 
taste panels for the aversive compound PZQ. The evaluated sensors of the electronic tongue in this 
study were not applicable for the compound PZQ due to the non-ionic characteristic and the low solubility 
of the drug in water. None of the tested sensors provided conclusive responses for the pure compound 
and hence for further evaluation of multicomponent systems. In contrast, the rats in the BATA model 
demonstrated a concentration-dependent sensitivity to the PZQ aversiveness leading to an IC50 value 
of 0.06 mg/ml. The BATA model was shown to be a useful taste assessment tool for PZQ for the 
comparison of formulations at an early stage in development, avoiding challenging human taste panels. 
Based on these findings the taste masking efficiency of liquid formulations for PZQ was evaluated and 
the use of MD was compared to two CDs. Despite the fact that the phase solubility study identified SBE-
β-CD as superior to HP-β-CD and the MD, the BATA model revealed the MD as efficient as both CDs 
to mask the aversive taste of PZQ. Moreover, SBE-β-CD was significantly less useful compared to the 
other formulations containing MD or HP-β-CD accompanied with a less acceptable taste of the pure 
excipient solution in the BATA model. This preference for the taste of the rodents needs to be confirmed 
in further human studies. As MDs are better tolerated excipients than CDs, they could provide a viable 
alternative in terms of taste-masking of liquids. The mechanisms of this efficient taste masking effect 
still needs to be further elucidated.  
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1Table 1
Labelling and membrane composition of the applied self-developed sensors.
Sensor labeling Ionophore Artificial lipid Oleic acid
A ßCD TB
B HPßCD TC
C CDO TC, BP x
D HPßCD TC
E HPßCD TC, BP
F TB x
G HPßCD TB x
Table 2
Classification of number of licks in the Brief Access Taste Aversion model (Soto, 2016).
Classification % lick inhibition
Fully tolerated 0
Well tolerated 1 – 30
Tolerated 30 – 50
Aversive/ untolerated 50 – 75
Highly aversive/ highly untolerated > 75
Table 3
Key figures calculated from the slope of the phase solubility study.
Excipient Slope K1:1 [M-1] CE PZQ: CD Increase in formulation bulk
HP-β-CD 0.14 228.71 0.16 1: 7.25 32.19
SBE-β-CD 0.21 365.11 0.26 1: 4.85 33.58
Maltodextrin N/A N/A N/A N/A N/A
Table 4
Comparative % lick inhibition of pure praziquantel (PZQ) in water and with the addition of 20 mM
hydroxypropyl-beta-cyclodextrin (HP-β-CD), 20 mM sulfobutyl ether-beta-cyclodextrin (SBE-β-CD) and 
20 mM maltodextrin (MD).
PZQ concentration
[mg/ml]
Pure PZQ PZQ + HP-β-CD PZQ + SBE-β-CD PZQ + MD
% lick inhibition
0 2.4 ± 2.2 23.9 ± 4.3 -4.3 ± 5.5
0.06 50 (IC50) 5.6 ± 3.3 22.4 ± 3.9 9.3 ± 4.6
0.2 72.0 ± 2.6 34.9 ± 3.6 66.3 ± 4.2 32.1 ± 5.0
0.27 44.7 ± 4.2
1.3 80.3 ± 2.3 90.9 ± 0.9
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Fig. 1. Phase solubility study. Solubilized concentration of praziquantel (PZQ) plotted against the
concentration of maltodextrin (MD, Kleptose® linecaps), hydroxypropyl-beta-cyclodextrin (HP-beta-CD,
Kleptose® HPB) and sulfobutyl ether-beta-cyclodextrin (SBE-beta-CD, Captisol®). Arithmetic mean ±
S.D. (n = 3).
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Fig. 2. Calibration for electronic tongue. Sensor signals of commercially available (SB2AC0, SB2AN0,
SB2AAE, SB2CT0, SB2CA0, SB2BT0) and self-developed sensors (Sensor A – G) of four different
concentrations of praziquantel in distilled water (0.01 – 0.5 mM). Arithmetic mean ± S.D. (n = 3).
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Fig. 3. Measurement of aftertaste of electronic tongue. Change of membrane potential of commercially
available (SB2AC0, SB2AN0, SB2AAE, SB2CT0, SB2CA0, SB2BT0) and self-developed sensors
(Sensor A – G) caused by adsorption (aftertaste) of four different concentrations of praziquantel in
distilled water (0.01 – 0.5 mM). Arithmetic mean ± S.D. (n = 3).
PZQ concentration [mg/ml]
0.000 0.005 0.010 0.030 0.050 0.100 0.200
N
um
be
ro
fl
ic
ks
0
10
20
30
40
50
Fig. 4. Calibration for BATA model. Recorded number of licks in BATA model as a function of
praziquantel (PZQ) concentration in water. Arithmetic mean (n = 80) ± S.E.M..
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Fig. 5. Comparison of taste masking efficacy in BATA model. Recorded number of licks in BATA model
as a function of praziquantel (PZQ) concentration of pure PZQ solution and the solutions with
hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and sulfobutyl ether-beta-cyclodextrin (SBE-beta-CD)
and maltodextrin (MD). The concentration of 0.000 mg/ml presents pure water in the case of PZQ and
pure 20 mM CDs or MD in the case of the formulations. Arithmetic mean (n = 80) ± S.E.M..
